| RS2524016367 |
STIL
|
Health Risk |
Pathogenic |
Myoepithelial tumor, Myoepithelial tumor |
| RS2524016687 |
MUTYH
|
Health Risk |
Pathogenic |
Familial adenomatous polyposis 2, Familial adenomatous polyposis 2 |
| RS2524017181 |
MUTYH
|
Health Risk |
Pathogenic/Likely pathogenic |
Hereditary cancer-predisposing syndrome, Familial adenomatous polyposis 2 |
| RS2524023943 |
MUTYH
|
Health Risk |
Pathogenic |
Familial adenomatous polyposis 2, Familial adenomatous polyposis 2 |
| RS2524026293 |
DPYD
|
Health Risk |
Likely pathogenic |
Dihydropyrimidine dehydrogenase deficiency, Dihydropyrimidine dehydrogenase deficiency |
| RS2524026345 |
DPYD
|
Health Risk |
Likely pathogenic |
Dihydropyrimidine dehydrogenase deficiency, Dihydropyrimidine dehydrogenase deficiency |
| RS2524027479 |
DOCK7
|
Health Risk |
Pathogenic |
Developmental and epileptic encephalopathy, 23 |
| RS2524028270 |
DOCK7
|
Health Risk |
Pathogenic |
Developmental and epileptic encephalopathy, 23 |
| RS2524035532 |
LDLRAP1
|
Health Risk |
Pathogenic |
Hypercholesterolemia, familial |
| RS2524047809 |
ABCA4
|
Health Risk |
Likely pathogenic |
— |
| RS2524047814 |
ABCA4
|
Health Risk |
Likely pathogenic |
— |
| RS2524048067 |
ABCA4
|
Health Risk |
Pathogenic |
— |
| RS2524048090 |
ABCA4
|
Health Risk |
Likely pathogenic |
— |
| RS2524050386 |
MUTYH
|
Health Risk |
Pathogenic |
Familial adenomatous polyposis 2, Familial adenomatous polyposis 2 |
| RS2524051238 |
MUTYH
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2524054030 |
VPS13D
|
Health Risk |
Likely pathogenic |
Autosomal recessive cerebellar ataxia-saccadic intrusion syndrome, Autosomal recessive cerebellar ataxia-saccadic intrusion syndrome |
| RS2524056466 |
VPS13D
|
Health Risk |
Pathogenic |
— |
| RS2524063273 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524063437 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524063471 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease type 2, Maple syrup urine disease type 2 |
| RS2524068789 |
LCA5
|
Health Risk |
Pathogenic |
— |
| RS2524070901 |
DMD
|
Health Risk |
Likely pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS2524071268 |
MUTYH
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Familial adenomatous polyposis 2 |
| RS2524072936 |
MUTYH
|
Health Risk |
Pathogenic |
Familial adenomatous polyposis 2, Familial adenomatous polyposis 2 |
| RS2524074403 |
DMD
|
Health Risk |
Likely pathogenic |
Neuromuscular disease caused by qualitative or quantitative defects of dystrophin, Neuromuscular disease caused by qualitative or quantitative defects of dystrophin |
| RS2524074680 |
DMD
|
Health Risk |
Pathogenic/Likely pathogenic |
Neuromuscular disease caused by qualitative or quantitative defects of dystrophin, Duchenne muscular dystrophy |
| RS2524074950 |
DMD
|
Health Risk |
Likely pathogenic |
Becker muscular dystrophy, Duchenne muscular dystrophy |
| RS2524075262 |
DMD
|
Health Risk |
Likely pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS2524078674 |
VPS13D
|
Health Risk |
Pathogenic |
Autosomal recessive cerebellar ataxia-saccadic intrusion syndrome, Autosomal recessive cerebellar ataxia-saccadic intrusion syndrome |
| RS2524082011 |
COL4A5
|
Health Risk |
Pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2524082382 |
COL4A5
|
Health Risk |
Likely pathogenic |
— |
| RS2524082406 |
COL4A5
|
Health Risk |
Likely pathogenic |
— |
| RS2524085166 |
MUTYH
|
Health Risk |
Conflicting classifications of pathogenicity |
Familial adenomatous polyposis 2, Hereditary cancer-predisposing syndrome |
| RS2524086364 |
ORC1
|
Health Risk |
Likely pathogenic |
— |
| RS2524086960 |
MUTYH
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Familial adenomatous polyposis 2 |
| RS2524090518 |
MUTYH
|
Health Risk |
Pathogenic/Likely pathogenic |
Familial adenomatous polyposis 2, Familial adenomatous polyposis 2 |
| RS2524094119 |
DPYD
|
Health Risk |
Likely pathogenic |
Dihydropyrimidine dehydrogenase deficiency, Dihydropyrimidine dehydrogenase deficiency |
| RS2524094344 |
DPYD
|
Health Risk |
Pathogenic |
Dihydropyrimidine dehydrogenase deficiency, Dihydropyrimidine dehydrogenase deficiency |
| RS2524099521 |
JAK1
|
Health Risk |
Pathogenic |
Autoinflammation, immune dysregulation |
| RS2524100144 |
LDLRAP1
|
Health Risk |
Pathogenic |
Hypercholesterolemia, familial |
| RS2524103427 |
USP26
|
Health Risk |
Pathogenic |
Spermatogenic failure, X-linked |
| RS2524106032 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease type 2 |
| RS2524106373 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524106384 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524106517 |
DBT
|
Health Risk |
Likely pathogenic |
DBT-related disorder, DBT-related disorder |
| RS2524109140 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524109142 |
LDLRAP1
|
Health Risk |
Pathogenic |
Hypercholesterolemia, familial |
| RS2524111305 |
LDLRAP1
|
Health Risk |
Pathogenic |
Cardiovascular phenotype, Familial hypercholesterolemia |
| RS2524112772 |
MUTYH
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2524122940 |
MUTYH
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Familial adenomatous polyposis 2 |
| RS2524123917 |
DMD
|
Health Risk |
Likely pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS2524124161 |
DMD
|
Health Risk |
Pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS2524124793 |
CAMTA1
|
Health Risk |
Pathogenic |
See cases, See cases |
| RS2524127154 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524127909 |
DMD
|
Health Risk |
Likely pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS2524128308 |
ATAD3A
|
Health Risk |
Likely pathogenic |
Harel-Yoon syndrome, Pontocerebellar hypoplasia |
| RS2524136302 |
LDLRAP1
|
Health Risk |
Likely pathogenic |
Cardiovascular phenotype, Cardiovascular phenotype |
| RS2524146862 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease type 1A, Maple syrup urine disease type 1A |
| RS2524146899 |
MUTYH
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2524147113 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease type 1A, Maple syrup urine disease type 1A |
| RS2524147212 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524147444 |
DBT
|
Health Risk |
Pathogenic/Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease type 2 |
| RS2524147800 |
DBT
|
Health Risk |
Pathogenic/Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524147997 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524148089 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524148155 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524148167 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524151547 |
MUTYH
|
Health Risk |
Pathogenic |
Familial adenomatous polyposis 2, Familial adenomatous polyposis 2 |
| RS2524152962 |
GLMN
|
Health Risk |
Likely pathogenic |
Glomuvenous malformation, Glomuvenous malformation |
| RS2524153154 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524153541 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524153852 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease type 1A, Maple syrup urine disease type 2 |
| RS2524154093 |
MUTYH
|
Health Risk |
Likely pathogenic |
Familial adenomatous polyposis 2, Familial adenomatous polyposis 2 |
| RS2524154110 |
GLMN
|
Health Risk |
Pathogenic |
Glomuvenous malformation, Glomuvenous malformation |
| RS2524154333 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524154447 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524154624 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524154961 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524157635 |
MUTYH
|
Health Risk |
Pathogenic |
Familial adenomatous polyposis 2, Familial adenomatous polyposis 2 |
| RS2524158214 |
MUTYH
|
Health Risk |
Pathogenic |
Familial adenomatous polyposis 2, Familial adenomatous polyposis 2 |
| RS2524158645 |
MUTYH
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Familial adenomatous polyposis 2 |
| RS2524160037 |
PAK3
|
Health Risk |
Likely pathogenic |
— |
| RS2524162250 |
COL4A5
|
Health Risk |
Likely pathogenic |
COL4A5-related disorder, COL4A5-related disorder |
| RS2524162277 |
COL4A5
|
Health Risk |
Pathogenic |
— |
| RS2524162428 |
COL4A5
|
Health Risk |
Pathogenic/Likely pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2524162796 |
COL4A5
|
Health Risk |
Pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2524162850 |
COL4A5
|
Health Risk |
Likely pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2524162912 |
COL4A5
|
Health Risk |
Likely pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2524162968 |
COL4A5
|
Health Risk |
Likely pathogenic |
— |
| RS2524163346 |
ORC1
|
Health Risk |
Pathogenic |
— |
| RS2524163534 |
ORC1
|
Health Risk |
Likely pathogenic |
Meier-Gorlin syndrome 1, Meier-Gorlin syndrome 1 |
| RS2524164373 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524164534 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524164669 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524164689 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524164698 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524164751 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease type 2, Maple syrup urine disease type 1A |
| RS2524165156 |
DBT
|
Health Risk |
Pathogenic/Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524165275 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2524179376 |
COL11A1
|
Health Risk |
Pathogenic |
— |